title: Is there a rationale for bladder cancer screening?
abstract: Screening should decrease disease-related mortality by detecting cancer before symptoms prompt evaluation. Several characteristics of bladder cancer make screening an attractive option. Nevertheless, premature adoption of a screening program has considerable negative consequences. This article reviews the current literature regarding screening for bladder cancer and emphasizes the need for prospective, clinical trials before considering practice modification.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Svatek
authors.forename: Yair
authors.initials: Y
authors.lastname: Lotan
mesh_terms: D014408:Biomarkers, Tumor / Q000652:urine; D003362:Cost-Benefit Analysis; D003558:Cystoscopy / Q000592:standards; D042241:Early Diagnosis; D005189:False Positive Reactions; D017048:Health Care Costs; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000379:methods / Q000592:standards; D015995:Prevalence; D012680:Sensitivity and Specificity; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000401:mortality
chemical_list: D014408:Biomarkers, Tumor